Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;145(2):429-443.
doi: 10.1007/s00432-019-02839-w. Epub 2019 Jan 7.

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Marco Gallo  1 , Valentina Guarnotta  2 , Federica De Cicco  3 , Manila Rubino  4 , Antongiulio Faggiano  3 , Annamaria Colao  3 ; NIKE Group
Collaborators, Affiliations
Review

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Marco Gallo et al. J Cancer Res Clin Oncol. 2019 Feb.

Abstract

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.

Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.

Results: We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?

Conclusion: The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited.

Keywords: Avelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

    1. Al Homsi MU, Mostafa M, Fahim K (2018) Favorable response to treatment with avelumabin an HIV-positive patient with advanced merkel cell carcinoma previously refractory to chemotherapy. Case Rep Oncol 11(2):467–475. 10.1159/000490636 - PMC - PubMed
    1. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE (2010) Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 37:20–27. 10.1111/j.1600-0560.2009.01370.x - PubMed
    1. Amaral T, Leiter U, Garbe C (2017) Merkel cell carcinoma: epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord 18:517–532. 10.1007/s11154-017-9433-0 - PubMed
    1. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. 10.1200/JCO.2014.58.3377 - PubMed
    1. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al (2016) Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transpl 51(3):443–445. 10.1038/bmt.2015.266 - PubMed

MeSH terms